carleton.edu
Cure8 news brief
Why This Matters
This reports preclinical Crohn’s disease research linking creeping fat to intestinal scarring and the creation of a mouse model to study fibrosis and test interventions — an early step toward therapies for strictures.
Who Should Pay Attention
Patients and caregivers concerned about Crohn’s-related strictures/fibrosis, researchers in IBD mechanisms and drug discovery, and students/alumni interested in translational research.
Study Snapshot
Story typeResearch paper
Evidence typeClinical study
Source depthFull source text
What To Know
This alumni profile describes Ben Pham ’23 joining a Stanford lab that studied mechanisms of Crohn’s disease.
The team looked at “creeping fat” (abnormal fatty tissue) and its role in intestinal scarring and fibrosis, developed a surgical mouse model of intestinal fibrosis to reproduce a stricture-like phenotype, and plans to use that model to test interventions aimed at treating strictures.
Pham’s role included learning wet-lab techniques and bioinformatics while contributing to the final two years of a five-year study. The piece emphasizes the move from mechanism discovery toward testing potential treatments using the new mouse model.
Keep In Mind
The article is an alumni profile summarizing a lab’s multi-year study and future preclinical work; it is not a clinical trial or treatment guideline. Outcomes and therapeutic implications remain preliminary and will require further research.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationcarleton.edu
Indexed viaGoogle News
Source typeResearch paper
PublishedJun 1, 2026, 5:43 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
This describes an investigational drug approach (PALI-2108) aimed at intestinal fibrosis, a key issue in fibrostenotic Crohn’s disease for which there are no approved antifibrotic therapies. Patients and clinicians may...
Crosstalk between circRNAs and the classic signaling pathways in IBD.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
Regulatory T cells for treatment of Crohn's disease
Treg cell therapy aims to reduce harmful immune activity that drives Crohn's disease. If developed successfully, it could become a targeted cell-based treatment option for patients who don't respond to current therapies.